SLQT:NYSESelectQuote, Inc. Analysis

SelectQuote trades well below its peers on valuation multiples. Its forward PE sits comfortably under the industry average, and the price‑to‑book is less than half of one. The stock also shows a sizable upside potential relative to current price. Margins remain modest but stable, with operating margins in the low‑teens and a positive free‑cash‑flow profile. Revenue growth is modest yet positive, and the company has reaffirmed its fiscal‑2026 outlook with revenue in the $1.6‑$1.7 billion range and adjusted EBITDA near $100 million. Management highlighted a targeted run‑rate for its SelectRx pharmacy platform in the $40‑$50 million range. Technical indicators are mixed: the 20‑day SMA sits above the 50‑day SMA, while the MACD has turned bearish and volume is trending down. The RSI is near the midpoint, suggesting no extreme momentum.
The stock’s beta is markedly high, amplifying market moves, and 30‑day volatility is extreme. The decreasing volume and neutral trend add to short‑term uncertainty. However, the company’s exposure is limited to the United States, reducing geographic risk. No dividend is paid, so income‑focused investors have limited appeal.